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Osteoclast inhibitors to prevent bone metastases in men with high-risk,
nonmetastatic prostate cancer: A systematic review and meta-Analysis
Abstract
Background: In advanced prostate cancer, osteoclast inhibitors prevent and palliate skeletal related events
associated with bone metastases. However, it is uncertain whether they play a disease-modifying role earlier in
the course of the disease.
Methods: Medline, EMBASE, Cochrane Central Register of Controlled Trials and Cochrane Database of
Systematic Reviews and ASCO conference proceedings were searched for randomized controlled trials that
compared osteoclast inhibitors with placebo and/or standard of care (SOC) in patients with high-risk, non-
metastatic prostate cancer. The primary outcome measure was incidence of new bone metastases; secondary
outcomes included overall survival (OS), prostate cancer specific survival, mortality unrelated to prostate
cancer, toxicity and health related quality of life outcomes. Results are presented as relative risk (RR) with
95% confidence intervals (CI).
Results: Six randomized controlled trials (5947 participants) were included, five evaluating bisphosphonates
and one denosumab. Overall, there was no difference in incidence of bone metastases between participants
treated with osteoclast inhibitors versus placebo/SOC (RR 1.09, 95%CI 0.84-1.41, p = 0.51) however
significant heterogeneity was observed between studies. The denosumab trial was the largest and only positive
trial amongst the included studies (RR 0.83, 95%CI 0.73-0.95, p = 0.007). No significant difference was
observed in OS (RR 0.99 95% CI 0.89-1.10, p = 0.84) nor prostate cancer specific survival (RR 1.12 95%CI
0.93-1.36, p = 0.24). Most studies reported increased rates of osteonecrosis of the jaw (5% or less) and
hypocalcemia (2% or less) with osteoclast inhibitors.
Conclusions: While there is limited evidence that bisphosphonates alter the natural history of high-risk, non-
metastatic prostate cancer, denosumab delays onset of bone metastases in this patient population. Neither
class of osteoclast inhibitor demonstrated an impact on survival outcomes. Future trials with better defined
patient selection and a robust definition for high risk disease is critical.
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Abstract
Background
In advanced prostate cancer, osteoclast inhibitors prevent and palliate skeletal related
events associated with bone metastases. However, it is uncertain whether they play a dis-
ease-modifying role earlier in the course of the disease.
Methods
Medline, EMBASE, Cochrane Central Register of Controlled Trials and Cochrane Database
of Systematic Reviews and ASCO conference proceedings were searched for randomized
controlled trials that compared osteoclast inhibitors with placebo and/or standard of care
(SOC) in patients with high-risk, non-metastatic prostate cancer. The primary outcome mea-
sure was incidence of new bone metastases; secondary outcomes included overall survival
(OS), prostate cancer specific survival, mortality unrelated to prostate cancer, toxicity and
health related quality of life outcomes. Results are presented as relative risk (RR) with 95%
confidence intervals (CI).
Results
Six randomized controlled trials (5947 participants) were included, five evaluating bisphos-
phonates and one denosumab. Overall, there was no difference in incidence of bone metas-
tases between participants treated with osteoclast inhibitors versus placebo/SOC (RR 1.09,
95%CI 0.84–1.41, p = 0.51) however significant heterogeneity was observed between stud-
ies. The denosumab trial was the largest and only positive trial amongst the included studies
(RR 0.83, 95%CI 0.73–0.95, p = 0.007). No significant difference was observed in OS (RR
0.99 95% CI 0.89–1.10, p = 0.84) nor prostate cancer specific survival (RR 1.12 95%CI
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0.93–1.36, p = 0.24). Most studies reported increased rates of osteonecrosis of the jaw (5%
or less) and hypocalcemia (2% or less) with osteoclast inhibitors.
Conclusions
While there is limited evidence that bisphosphonates alter the natural history of high-risk,
non-metastatic prostate cancer, denosumab delays onset of bone metastases in this patient
population. Neither class of osteoclast inhibitor demonstrated an impact on survival out-
comes. Future trials with better defined patient selection and a robust definition for high risk
disease is critical.
Introduction
Prostate cancer is the second most common cancer in men worldwide [1] and, in advanced
disease, the skeleton is the dominant site of metastases [2]. Bone metastases can cause signifi-
cant morbidity including pain, pathological fractures, spinal cord compression and occa-
sionally, hypercalcemia. In addition, hospitalization with skeletal related events (SREs) is
associated with high health economic burden [3].
A cornerstone of management in men with advanced disease includes the prevention and
palliation of SREs. The nitrogen-containing, third generation bisphosphonate, zoledronic acid,
became standard of care for men with castrate resistant prostate cancer (CRPC) and bone
metastases after a phase III trial demonstrated a 35% reduction in SREs compared with pla-
cebo; a composite endpoint that included pathologic fractures, radiotherapy to bone, surgery
to bone, and spinal cord compression [4]. In a similar population, denosumab, a receptor acti-
vator of nuclear factor kappa-B (RANK) ligand antibody, was later compared to zoledronic
acid and found to further prolong the time to first SRE (20.7 months versus 17.1 months;
p = 0.008 for superiority) [5].
Recently, there has been increasing interest in the role of osteoclast inhibitors in the preven-
tion of bone metastases. The bone dominant nature of prostate cancer is thought to arise from
the complex interactions between tumor cells and the bone microenvironment [6, 7]. Activa-
tion of osteoclasts has been shown to play an important role in the development of prostate
cancer bone metastases [8, 9]. Furthermore, preclinical studies suggest that the inhibition of
osteoclast activation may impede the development or progression of bone metastases [10–12].
A phase III trial published by Smith et al [13] was the first clinical study to demonstrate a sig-
nificant delay in the development of bone metastases with denosumab compared with placebo
in patients with CRPC (33.2 versus 29.5 months; HR 0.84, p = 0.032).
Prevention of bone metastases remains a major unmet clinical need. Following the intro-
duction of prostate specific antigen (PSA) screening, the rates of men presenting with meta-
static disease is falling and the opportunity to intervene and alter the natural history of
prostate cancer in select, high-risk patients has never been greater. The role of osteoclast inhib-
itors in the prevention of bone metastases in men with high-risk, non-metastatic (M0) prostate
cancer remains uncertain. We aimed to assess the effects of osteoclast inhibitors on incidence
of new bone metastases and the relative harms of treatment in this population.
Osteoclast inhibitors to prevent bone metastases in high-risk prostate cancer
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Methods
Study protocol and registration
This study has no protocol. Methods are reported according to the Preferred Reporting for
Systematic Reviews and Meta-Analyses (PRISMA) guidelines (S1 PRISMA Checklist) [14].
Study selection criteria
We included all randomized controlled studies that compared bisphosphonates or denosumab
with placebo and/or standard of care (SOC) in patients with high-risk, M0 prostate cancer. For
inclusion in the quantitative analysis, studies were required to compare the efficacy of osteo-
clast inhibitors on incidence of bone metastases or overall survival. The primary outcome mea-
sure was incidence of bone metastases; secondary outcomes included overall survival, prostate
cancer specific survival, mortality unrelated to prostate cancer, toxicity and health related qual-
ity of life (HRQOL) outcomes.
Search strategy
The following databases were searched for randomized controlled trials fulfilling the above cri-
teria: Medline (1946 to October 13, 2016), EMBASE (1974 to October 13, 2016), Cochrane
Central Register of Controlled Trials and Cochrane Database of Systematic Reviews and
ASCO conference proceedings. The search strategy can be found in S1 Appendix and was
designed to maximize sensitivity. Bibliography searches of identified studies were then
checked for additional source material. Searches were restricted to English language
publications.
Quality and risk of bias assessment
Each study was assessed for quality and bias using the Cochrane Collaboration Risk of Bias
Tool [15] and the PRISMA guidelines [14], with particular focus on the domains of random
sequence generation, allocation concealment, allocation and outcome blinding, withdrawals
and loss to follow-up, intention-to-treat analysis and selective reporting. The results were pre-
sented as risk of bias tables, a risk of bias summary and risk of bias graph.
Data collection
Two authors (AH, DB) independently reviewed full-text manuscripts of included studies and
extracted data related to study characteristics and study quality with disagreement resolved by
consensus with a third author (NP). The specific documented details included accrual period,
median follow-up, country of study, sample size, methods of randomization, blinding, with-
drawals, completeness of follow-up, use of intention-to-treat analysis, included definitions of
high-risk prostate cancer, mean age, castration sensitive or refractory disease status, Gleason
score, disease stage, baseline PSA, prior local therapy, osteoclast inhibitor regimen and compli-
ance, methods of evaluation of bone metastases and follow-up, primary and secondary end-
points and outcomes.
Summary measures and methods of analysis
The principal summary measure used for the meta-analyses was risk ratio using the Mantel-
Haenszel method and a random effect model using RevMan 5.3 analysis software (The Nordic
Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark). Point estimate of
risk ratios and 95% confidence intervals (CI) are provided along with forest plots. Statistical
Osteoclast inhibitors to prevent bone metastases in high-risk prostate cancer
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heterogeneity was assessed using the I2 statistic. Formal analysis of publication bias was not
performed due to insufficient number of trials in any comparison. Pre-specified subgroup
analysis for incidence of bone metastases was performed based on drug class of osteoclast
inhibitor given their different mechanisms of action.
Results
Study selection
The search criteria identified 1,897 potential studies for inclusion, with 330 studies selected for
abstract review, and 10 selected for full-text review (Fig 1). The majority of studies were not
suitable for inclusion as they were not randomized trials, had an irrelevant comparator or
inappropriate outcome, did not include participants with non-metastatic prostate cancer or
were duplicate data. Of the 10 studies included for full-text review, three did not study an
appropriate outcome and one did not include participants with M0 prostate cancer.
Study characteristics
Six studies (5,947 participants) met the inclusion criteria of the systematic review and were
included for quality assessment and data extraction (Fig 1). One study (398 participants) was
terminated early due to low event rate and did not have published data suitable for inclusion
in the pooled analysis [16, 17].
The range of median follow-up was 3.6–11.5 years (Table 1). The study sample sizes ranged
from 398–1432 participants. The age (median 65–74 years) and performance status (ECOG 0/
1 96–100%) of participants was similar between the trials but the patient characteristics denot-
ing risk of bone metastases significantly varied (Table 2). There were also differences in mech-
anism of action of osteoclast inhibitor, frequency of drug administration and differences in
standard of care regimens across the studies (Table 1 and S1 Table).
For the MRC PR04 trial [19], data for overall survival was taken from the initial study
(median follow-up 118 months) as published data suitable for calculation of risk ratio was not
available from the follow-up study (median follow-up 138 months) [18]. STAMPEDE [22]
included patients with M0 and M1 disease, however, only those participants with M0 disease
were included in the quantitative analysis. STAMPEDE [22] incorporated incidence of bone
metastases into a composite outcome, failure free survival, and therefore could not be included
in the primary outcome quantitative analysis.
Treatment arm. Five studies included a treatment drug regimen with a bisphosphonate;
MRC PR04 [19] used the first generation, non-nitrogenous oral bisphosphonate, clodronate,
while the other four studies [16, 20–22] used the more potent, third generation, nitrogen-con-
taining bisphosphonate, zoledronic acid administered intravenously. The frequency of zole-
dronic acid administration varied between 4 mg every 4 weeks and every 12 weeks. Treatment
duration varied between 18 months and 4 years. One study [13] investigated denosumab,
which binds and inhibits RANK ligand, thus inhibiting RANK pathway signaling, which in
turn inhibits osteoclast differentiation and activation.
Control arm. The control regimen in all studies was SOC and/or placebo. There was vari-
ation between the studies in terms of what treatments constituted standard of care (Table 1
and S1 Table). For example, STAMPEDE [22] and RADAR [20] included ADT and radiother-
apy as SOC. The Zometa 704 [16] and Smith 2012 [13] trials allowed prior or concomitant
therapy deemed necessary by the treating clinician including antineoplastic agents.
Definition of high-risk prostate cancer. There was large heterogeneity in definitions of
high-risk prostate cancer across the studies. The Zometa 704 [16, 17] and Smith 2012 [13] tri-
als, both required PSA to be rising despite ADT and hence were studies of castrate resistant
Osteoclast inhibitors to prevent bone metastases in high-risk prostate cancer
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disease, in contrast to the other studies which included participants with castrate sensitive dis-
ease. Smith 2012 [13] also specified that PSA must be greater than 8 μg/L and/or have a dou-
bling time10 months denoting particularly high risk. The ZEUS [21], RADAR [20] and
STAMPEDE [22] trials used different combinations of tumor stage, Gleason score and PSA
score to define high risk but PSA doubling time was not specified as an inclusion criteria. The
MRC PR04 [19] only included tumor stage as part of the high risk definition. Hence, there was
large variation between the studies in proportion of participants with Gleason score >7, N
Fig 1. Flow diagram of study selection.
https://doi.org/10.1371/journal.pone.0191455.g001
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Table 1. Characteristics of included studies.
Trial Median follow-
up (years)
n Treatment arm Control arm Primary outcome
Zometa 704 [16,
17]
Trial terminated
after 3 years
398 ZA 4 mg q4weekly for 49 cycles Placebo Time to first bone metastasis
MRC PR04 [18,
19]
11.5 508 Clodronate 2080 mg/day for up to 5
years
SOC (Radiotherapy and/or ADT)
+ Placebo
Time to first symptomatic bone
metastasis or prostate cancer death
Smith 2012 [13] NR 1432 Denosumab 120 mg q4weekly SOC (ADT +/- antineoplastic
agents) + Placebo
Time to first bone metastasis
(symptomatic or asymptomatic) or
death from any cause
TROG 03.04
RADAR [20]
7.4 1071 ZA 4 mg q3monthly for 18 months Short (6 mo)- or intermediate (18
mo)-term ADT + definitive
radiotherapy
Prostate cancer specific mortality
ZEUS [21] 4.8 1393 ZA 4 mg q3monthly for up to 4
years
SOC (ADT) Incidence of bone metastases on bone
imaging at 4 ± 0.5 years
STAMPEDE [22] 3.6 1145 (M0);
1817 (M1)
ZA (4 mg every 3 weeks for 6 cycles,
then q4weekly until 2 years);
docetaxel† and ZA
SOC (ADT); Radiotherapy at 6–9
mo post-randomization‡
Overall survival and failure free
survival
Abbreviations: M0, non-metastatic; M1, distant metastatic disease; ADT, androgen deprivation therapy; ZA, zoledronic acid; SOC, standard of care; NR, not reported
 Planned accrual 991
† 75 mg/m2 q3weekly for 6 cycles with prednisone 10 mg daily
‡ Radiotherapy at 6–9 months after randomization was encouraged for participants with N0M0 disease until Nov 2011, then mandated. Radiotherapy was optional for
participants with N+M0 disease.
https://doi.org/10.1371/journal.pone.0191455.t001
Table 2. Participant characteristics denoting metastasis risk.
Trial Stage and high risk definition Hormone
status
Gleason
score > 7
Median PSA at
randomization (μg/L)
N
+ disease
T3/4
disease
Prostatectomy and/or
radiotherapy
Zometa 704 [16,
17]
M0; rising PSA despite ADT Castrate
resistant
29% 13.8 17% NR 34%
MRC PR04 [18,
19]
M0; T2–4 Castrate
sensitive
NR 13.0 (TG); 10.0 (CG) 3% 47% 71%
Smith 2012 [13] M0; rising PSA despite ADT; PSA
8 μg/L and/or PSA DT10 mo
Castrate
resistant
32% 12.2 13% NR 45%
TROG 03.04
RADAR [20]
M0; T2a (Gleason >7 and PSA10 μg/
L); or T2b–4, N0
Castrate
sensitive
35% 14.0–15.0 0%‡ 37% Radiotherapy planned
in 98%
ZEUS [21] M0; Gleason 8–10 or pN+ or PSA at
diagnosis>20 μg/L
Castrate
sensitive
62% 40.0† 24% NR 55%
STAMPEDE [22] M1 or M0; high-risk (at least two of T3/
4, Gleason 8–10 or PSA40 μg/L)
starting ADT
Castrate
sensitive
71% 65.0 50% 82% 60%§
Abbreviations: M0, non-metastatic; M1, distant metastatic disease; PSA, prostate specific antigen; DT, doubling time; ADT, androgen deprivation therapy; TG,
treatment group; CG, control group; SOC, standard of care; NR, not reported
 14.9 (Short term androgen suppression control group), 14.0 (Short term androgen suppression treatment group), 15.0 (Intermediate term androgen suppression
control group), 14.0 (Intermediate term androgen suppression treatment group)
† Mean PSA at diagnosis
‡ N+ disease excluded
§ Radiotherapy reported in 60% of M0 cohort
https://doi.org/10.1371/journal.pone.0191455.t002
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+ disease status and median PSA at baseline (Table 2). Rates of prior prostatectomy and/or
radiotherapy also varied between the trials (Table 2).
Risk of bias
The overall quality was good for the trials included in the quantitative analysis (S2 Table, S1
and S2 Figs). The Zometa 704 [16, 17] was difficult to assess due to paucity of published data;
there was no information provided on random sequence generation, allocation concealment,
blinding of outcome assessment, incomplete outcome data and selective reporting. The
STAMPEDE [22], RADAR [20] and ZEUS [21] trials were open-labeled and not placebo-con-
trolled and hence were at risk of performance bias. Smith 2012 [13], ZEUS [21] and Zometa
704 [16] had good descriptions of the imaging schedule and what clinical parameters or symp-
toms would prompt repeat imaging whereas STAMPEDE [22], RADAR [20] and MRC PR04
[19] did not.
For all the studies, except Smith 2012 [13] and ZEUS [21], it was unclear if there was blind-
ing of outcome assessment in regards to new bone metastases. Only Smith 2012 [13] reported
central radiology review in the entire study cohort. ZEUS reported central radiology review
in a subset of patients. In addition, only Smith 2012 [13], ZEUS [21] and Zometa 704 [16]
reported that bone metastases seen on bone scan were confirmed on plain radiographs, com-
puted tomography (CT) or magnetic resonance imaging (MRI). The MRC PR04 [19] did not
report how symptomatic bone metastases were confirmed radiologically.
All studies had acceptable losses to follow-up and all studies, except Zometa 704 [16, 17],
reported intention-to-treat analysis. There were no studies at risk of selective reporting bias.
Measurement of effect
Incidence of new bone metastases. Four studies (4,404 participants) investigated the
effect of osteoclast inhibitors on incidence of new bone metastases. There was no evidence of a
difference in incidence of new bone metastases between osteoclast inhibitors and placebo and/
or SOC when all four studies were pooled (RR 1.09, 95%CI 0.84–1.41, p = 0.51). However, this
method resulted in substantial heterogeneity (I2 71%, p = 0.008) between studies (Fig 2).
A subgroup analysis of only the bisphosphonate trials showed reduced heterogeneity (I2
33%) however there was no difference in incidence of bone metastases between bisphospho-
nates and placebo/SOC (RR 1.20, 95%CI 0.95–1.52, p = 0.12). The STAS (short term androgen
suppression) arm of the RADAR trial is noted to be an outlier and when this is removed from
the analysis, the heterogeneity is reduced (RR 1.10, 95%CI 0.90–1.34, p = 0.35, I2 0%) (S3 Fig).
The denosumab trial [13] is the largest and only positive trial amongst the included studies
(RR 0.83, 95%CI 0.73–0.95, p = 0.007) and denosumab has a significantly different mechanism
of action compared with bisphosphonates. It is therefore considered separately from the bis-
phosphonate trials to prevent dilution of any observed effect (Fig 2). There is evidence of sig-
nificant heterogeneity between the bisphosphonate versus denosumab subgroups (I2 86%,
p = 0.007 test for subgroup differences) and important differences between the bisphosphonate
trials and Smith 2012 [13] must be considered.
Overall survival. There was no difference in all-cause mortality between osteoclast inhibi-
tors and placebo/SOC (5 studies, 5549 participants, RR 0.99 95% CI 0.89–1.10, p = 0.84)
(Fig 3).
Prostate cancer specific survival. There was no difference in prostate cancer mortality
between bisphosphonates and placebo and/or SOC (3 studies, 2972 participants, RR 1.12 95%
CI 0.93–1.36, p = 0.24) (Fig 4).
Osteoclast inhibitors to prevent bone metastases in high-risk prostate cancer
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Fig 2. Forest plot for incidence of new bone metastases. Abbreviations: ITAS, intermediate term androgen suppression; STAS, short term androgen
suppression; ZA, zoledronic acid.
https://doi.org/10.1371/journal.pone.0191455.g002
Fig 3. Forest plot for overall survival. Abbreviations: ITAS, intermediate term androgen suppression; STAS, short term androgen suppression; ZA,
zoledronic acid.
https://doi.org/10.1371/journal.pone.0191455.g003
Fig 4. Forest plot for prostate cancer specific survival. Abbreviations: ITAS, intermediate term androgen suppression; STAS, short term androgen
suppression; ZA, zoledronic acid.
https://doi.org/10.1371/journal.pone.0191455.g004
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Mortality unrelated to prostate cancer. There was a trend towards reduced non-prostate
cancer related death with bisphosphonates (3 studies, 2972 participants, RR 0.84, 95%CI 0.69–
1.01) (Fig 5). However, this did not attain significance (p = 0.07).
HRQOL and toxicity. Five studies [13, 19–22] reported on toxicity and one study [23]
reported on HRQOL. Reporting measures differed between trials and only three trials [13, 20,
22] reported the use of standardized measurement common terminology criteria for adverse
events (CTCAE) criteria. There was insufficient published data for a quantitative analysis, and
qualitative results are summarized in Table 3. In general, there was a higher incidence of osteo-
necrosis of the jaw (5% or less) and hypocalcemia (2% or less) in the osteoclast inhibitor arms
compared with placebo/SOC, although these rates were small.
Discussion
This meta-analysis of four randomized controlled trials including 4,404 participants with
high-risk, M0 prostate cancer did not show evidence of a significant difference in incidence of
bone metastases between osteoclast inhibitors and placebo/SOC. However, caution is required
in interpreting these results as pooling of the studies led to significant heterogeneity between
the bisphosphonate and denosumab trials. Hence, the denosumab and bisphosphonate trials
need to be considered separately.
Smith 2012 [13], is a randomized controlled trial of 1,432 participants that compared deno-
sumab with placebo in the high-risk, M0, prostate cancer population and is the largest study
included in our meta-analysis. It showed delay in onset of bone metastases when denosumab
Fig 5. Forest plot for mortality unrelated to prostate cancer. Abbreviations: ITAS, intermediate term androgen suppression; STAS, short term
androgen suppression; ZA, zoledronic acid.
https://doi.org/10.1371/journal.pone.0191455.g005
Table 3. Toxicity and HRQOL outcomes.
Study Reporting measure Outcomes
Smith 2012 [13] CTCAEv3 Increased toxicity with denosumab; osteonecrosis of the jaw (33 vs. 0) and hypocalcemia (12 vs. 2)
ZEUS [21] Unclear; no measure
reported
Increased toxicity with ZA; influenza-like symptoms of general low severity such as muscle/bone pain,
arthralgia, fever, nausea and dizziness; osteonecrosis of the jaw in 10 patients (9 vs. 1); hypocalcemia in five
patients (4 vs. 1); femoral head osteonecrosis in one patient not considered ZA related (1 vs. 0).
TROG 03.04 RADAR
[20, 23]
CTCAEv2; EORTC QLQC30
and PR25
The use of ZA for 18 months did not appear to be associated with any independent effects on patient reported
outcomes and HRQOL. Nine participants had serious adverse events potentially related to ZA (osteonecrosis
jaw (2), urticaria (1), syncope during infusion (1), hypotension after infusion (1), renal pain related to
hydronephrosis (1), pyrexia and chest pain (1).
MRC PR04 [19] Non-standardized measure Increased toxicity with clodronate (gastrointestinal symptoms and increased lactate dehydrogenase levels)
STAMPEDE [22] CTCAEv3.0 Thirty cases of osteonecrosis of the jaw in ZA arms of trial (10 in SOC + ZA; 20 in SOC + ZA + docetaxel)
Abbreviations: ZA, zoledronic acid; SOC, standard of care; CTCAE, common terminology criteria for adverse events; HRQOL, health related quality of life; EORTC,
European Organisation for Research and Treatment of Cancer; QLQC30, quality of life questionnaire—core questionnaire; PR25, prostate cancer questionnaire
 adverse events defined as events leading to alteration in trial medication, hospitalization, prolongation of hospitalization or death.
https://doi.org/10.1371/journal.pone.0191455.t003
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was compared with placebo (RR 0.83, p = 0.007) and is the only positive trial in the included
studies. Further subgroup analysis, by Smith et al [24], demonstrated that shorter bone metas-
tasis free survival was observed as PSA doubling time decreased below 8 months and that
denosumab consistently increased bone metastasis free survival in participants with shorter
PSA doubling times (median of 6, 7.2 and 7.5 months among men with PSA doubling times
10 (HR 0.84; p = 0.042),6 (HR 0.77; p = 0.006), and4 months respectively (HR 0.71;
p = 0.004).
Denosumab has a fundamentally different mechanism of action compared to bisphospho-
nates. Denosumab is a fully human monoclonal IgG2 antibody which inhibits RANKL from
binding to its receptor, RANK, a critical element for osteoclast formation, function and sur-
vival and thereby leads to loss of osteoclasts from bone surfaces [25]. It primarily acts in the
extracellular milieu. In contrast, bisphosphonates, synthetic analogues of pyrophosphate, bind
to bone mineral and need to be internalized to act upon cells. The exact mechanism is
unknown, but they likely inhibit osteoclast function through intracellular effects, once taken
up by mature osteoclasts at sites of bone resorption [25]. Moreover, osteoclast inhibitors
appear to have a complex interaction with the bone marrow microenvironment, a rich source
of bone-derived growth factors (e.g. transforming growth factor-beta, insulin-like growth fac-
tor) and immune cells, which are likely to play important roles in the regulation of tumor cell
growth in bone [26–28]. In addition, denosumab and nitrogen-containing bisphosphonates
(e.g. zoledronic acid) may also have osteoclast-independent, direct anti-tumor activity via dif-
ferent mechanisms of action, although further research is needed [29, 30]. Interestingly, there
is preclinical evidence that suggests an immune-mediated anti-tumor effect mediated via
RANKL inhibition [31, 32].
While the difference in drug mechanism of action is the most critical factor to explain the
difference in efficacy between the bisphosphonate and denosumab trials, it is important to
consider other differences in the trial designs and study populations that may have also con-
tributed to heterogeneity. All participants in the denosumab trial [13] had castrate resistant
disease and had to meet one of two PSA criteria (PSA8 μg/L and/or PSA doubling time10
months) making them higher risk candidates for bone metastases compared with the partici-
pants in the other studies. It was also the only trial that mandated regular (4 monthly) bone
scans throughout the trial period. Given that the majority of bone metastases detected in
Smith 2012 [13] were asymptomatic (440/605; 73%), the more regular imaging may have
increased the sensitivity to detect a treatment effect. Furthermore, this was the only trial with
central review of bone imaging for the entire trial cohort, reducing the risk of detection bias.
Finally, it is the only study in the quantitative analysis that allowed concomitant antineoplastic
therapy. However, the use of chemotherapy or biological agents was reported to be balanced
between the intervention and comparator groups with no notable differences in treatment
type.
When drug classes were considered separately, there was no evidence that bisphosphonates
delay the onset of bone metastases (HR 1.20, p = 0.12, I2 33%), in contrast to denosumab (RR
0.83, p = 0.007). Furthermore, in one of the bisphosphonate trials, the short term androgen
suppression arm (STAS, 6 months) of the RADAR study [20], showed a higher incidence of
new bone metastases in the bisphosphonate arm. It is unclear why a significant increase in
bone progression was noted in STAS plus zoledronic acid compared with STAS alone, particu-
larly as no difference was noted between the intermediate term androgen suppression arm of
the same trial (18 months). In a post-hoc analysis, the difference between STAS plus zoledronic
acid and STAS, was most notable in tumors with Gleason score less than 7, compared to a
non-significant difference in tumors with Gleason score 8–10 [20]. We were unable to perform
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a subgroup analysis based on Gleason score due to insufficient published data and this deserves
the attention of further research.
We did not demonstrate any impact of osteoclast inhibitors on either overall survival or
prostate cancer specific survival. These results mirror those of a recently published review by
Vale et al [33], despite the additional inclusion of the denosumab trial [13]. Interestingly, there
was a non-significant trend towards decreased mortality unrelated to prostate cancer with bis-
phosphonates, consistent with recent work which showed a reduced all-cause mortality in the
osteoporosis population independent of fracture prevention [34, 35]. However, it is important
to view this result in the context of unaltered overall survival.
A quantitative analysis was unable to be performed on toxicity and HRQOL outcomes as
the reporting methods differed between the trials. Most studies reported increased incidence
of osteonecrosis of the jaw and hypocalcemia in the treatment arm but incidence rates were
very low. It is important to note, however, that incidence rates were higher in the more
recently performed trials likely due to more diligent detection protocols. In addition, Smith
2012 [13] reported that 94% of those men who had osteonecrosis of the jaw had pre-existing
oral risk factors, including tooth extraction, poor oral hygiene and dental application use. It is
reasonable to assume that if men were selected more carefully for osteoclast inhibitor therapy
the incidence of osteonecrosis of the jaw could be reduced. Similarly, in terms of the complica-
tion of hypocalcemia, no trial reported participant’s 25-hydroxyvitamin D levels prior to
commencing treatment and only two trials [16, 21] mandated concomitant vitamin D3 and
calcium supplementation. With more careful screening of participants and supplemental cal-
cium and vitamin D3, the incidence of hypocalcemia with osteoclast inhibitors could also be
reduced.
There are several limitations to our review. Firstly, frequency of drug administration dif-
fered between the zoledronic acid studies (monthly vs. q3monthly). Exploratory studies sug-
gest that cancer patients with elevated bone turnover markers have a higher risk of bone
progression [36] and that q3monthly administration of zoledronic acid is not adequate to sup-
press markers of bone turnover [37, 38]. In contrast to the denosumab trial [13], many of the
bisphosphonate trials included in our quantitative analysis did not measure markers of bone
turnover to confirm adequate suppression of bone resorption. Secondly, there was large varia-
tion in characteristics of the participants in terms of their risk of bone metastases and more
importantly, their prognosis (e.g. hormone status, PSA, Gleason score, tumor stage). Thirdly,
the majority of the trials did not mandate a regular imaging schedule but instead allowed imag-
ing at the clinician’s discretion potentially resulting in under-detection of bone metastases.
Finally, in the absence of bone marrow biopsy [39] and imaging with high sensitivity for occult
bone metastases (e.g. 68Ga-PSMA PET/CT or whole body diffusion weighted MRI [40–42]), it
is likely that many patients, especially those with castrate resistant disease, had the presence of
micrometastases or small metastases below the detection of scintigraphy, on trial enrollment.
Hence, our analysis was only able to assess the impact of osteoclast inhibitor therapy on the
delay of onset of radiologically-detectable bone metastases, rather than their true prevention.
Overall, our meta-analysis demonstrates limited impact of osteoclast inhibitors in men with
high-risk, M0 prostate cancer however interpretation is limited by significant heterogeneity
between the bisphosphonate and denosumab studies likely due to pooling of drug classes with
different mechanisms of action. While there was no benefit seen with bisphosphonates, the
denosumab trial, Smith 2012 [13], demonstrated a significant delay in the onset of bone metas-
tases in this population. Our results highlight the critical need for further trials selecting men
at true high risk of bone metastases, which incorporate castrate resistant disease status, short
PSA doubling times and high Gleason score at baseline. Furthermore, as modern imaging
with greater sensitivity to detect occult bone metastases, like 68Ga-PSMA PET/CT, becomes
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incorporated into practice, it will become increasingly difficult to apply evidence from these
trials in the bygone era.
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